Since, in human lung cancer patients, plasma IL-1β levels correlate with a poor prognosis, and bortezomib treatment led to an increase in IL-1β levels [52], the above-mentioned mouse study can be translated to human lung cancer as well. Here, IL1B is linked to lung cancer.